Citigroup Inc Eye Point Pharmaceuticals, Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Eye Point Pharmaceuticals, Inc. stock. As of the latest transaction made, Citigroup Inc holds 46,509 shares of EYPT stock, worth $487,879. This represents 0.0% of its overall portfolio holdings.

Number of Shares

46,509

Previous 20,646 125.27%

Holding current value

$487,879

Previous $179,000 107.26%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$7.58 - $10.54 $196,041 - $272,596	25,863 Added 125.27%	46,509 $371,000
Q2 2024 Aug 12, 2024	SELL	$8.16 - $22.89 $565,618 - $1.59 Million	-69,316 Reduced 77.05%	20,646 $179,000
Q1 2024 May 10, 2024	BUY	$19.93 - $29.71 $1.7 Million - $2.53 Million	85,290 Added 1825.56%	89,962 $1.86 Million
Q4 2023 Feb 09, 2024	BUY	$5.71 - $24.13 $26,608 - $112,445	4,660 Added 38833.33%	4,672 $107,000
Q3 2023 Nov 09, 2023	SELL	$7.99 - $15.36 $62,218 - $119,608	-7,787 Reduced 99.85%	12 $0
Q2 2023 Aug 10, 2023	BUY	$3.03 - $9.0 $23,630 - $70,191	7,799 New	7,799 $67,000
Q4 2022 Feb 09, 2023	SELL	$2.37 - $7.2 $1,431 - $4,348	-604 Reduced 77.44%	176 $0
Q3 2022 Nov 10, 2022	SELL	$6.96 - $11.12 $12,061 - $19,270	-1,733 Reduced 68.96%	780 $6,000
Q2 2022 Aug 10, 2022	BUY	$7.25 - $12.71 $4,386 - $7,689	605 Added 31.71%	2,513 $20,000
Q1 2022 May 12, 2022	SELL	$8.67 - $14.11 $38,728 - $63,029	-4,467 Reduced 70.07%	1,908 $24,000
Q4 2021 Feb 10, 2022	BUY	$10.18 - $18.4 $40,363 - $72,956	3,965 Added 164.52%	6,375 $78,000
Q3 2021 Nov 10, 2021	BUY	$7.51 - $11.72 $18,099 - $28,245	2,410 New	2,410 $25,000

Others Institutions Holding EYPT

# of Institutions

150

Shares Held

58M

Call Options Held

177K

Put Options Held

263K

View Full List

About EyePoint Pharmaceuticals, Inc.

Ticker EYPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,072,200
Market Cap $357M
Description
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intrav...

More about EYPT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account